Cholangiocarcinoma of the Gallbladder Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0029558 (Cholangiocarcinoma of the Gallbladder)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00356889Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsTreatment